Real Time Genomics, Inc., and Omicia, Inc. today announced a commercial partnership to deliver genome analytics for the clinical interpretation of genomes for childhood diseases.
Omicia announced the appointment of former National Genetics Institute CEO Mike Aicher as Chief Executive Officer and member of the company’s Board of Directors.
Omicia and University of Utah win the 2012 Grand Prize in Personalized and Translational Medicine at the Bio-IT Best Practices Awards competition.
Omicia, Inc. announced today that it has initiated an early access program for its individual genome interpretation product. Through this product, Omicia will enable users to prioritize and identify disease genes and their variants using an intuitive and interactive web-based application environment.
VAAST — the Variant Annotation, Analysis and Selection Tool — was developed by Omicia Inc. and the University of Utah to allow medical researchers to rapidly identify gene variants.
At the International Congress of Human Genetics meeting held last month in Montreal, Quebec, representatives from Omicia, Inc. discussed near-term applications of their tools, including how they may be used in the clinic.
A data interpretation bottleneck has limited the utility of personal genome information for medical diagnosis and preventive care. VAAST, developed by Omicia, Inc. and the University of Utah, is a new algorithm to assist in overcoming this bottleneck.
The cost of sequencing an individual’s entire genome has fallen precipitously over the past five years, from around $100 million for the first personal genome to under $5,000 today when sequencing services are purchased in bulk.
Scientists from the University of Utah and Omicia, Inc. have developed a software package that requires a relatively small sample size to functionally interpret whole-genome sequence data which they claim is more accurate than existing methods.
Following a proof of principle for its disease-gene finding algorithm, genome interpretation startup Omicia plans to launch a platform for the clinical analysis of human genomes later this year.
